Search clinical trials for: recurrent ovarian epithelial cancer

Total 97968 results

Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer

Breast Cancer | Fatigue | Ovarian Cancer | Psychosocial Effects of Cancer and Its Treatment

United States
National Cancer Institute (NCI)

Completed

RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer

United States, Canada
Fred Hutchinson Cancer Center

Completed

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma and other conditions

United States
Genentech, Inc.

Completed

A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed

Ovarian Cancer
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Blood Samples From Patients on a Clinical Trial to CINV During HSCT

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms | Nausea and Vomiting

United States
OHSU Knight Cancer Institute

Completed

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Cancer

United States
University of Louisville
Penn State University

Completed

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Massachusetts General Hospital
Bayer; Dana-Farber Cancer Institute

Completed

GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer
Stanford University

Terminated

Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Recurrent Ovarian Epithelial Cancer | Recurrent Ovarian Germ Cell Tumor | Malignant Tumor of Peritoneum

United States
Tesaro, Inc.

Approved for marketing

Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Cancer
Genentech, Inc.

Completed

A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer

Ovarian Cancer
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (GVHD)

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal... and other conditions

United States
AstraZeneca
RTI Health Solutions; A+A Healthcare Marketing Research; Freelance CRA (FCRA)

Completed

OSCA - Olaparib Standard of CAre Study (OSCA)

Platinum-sensitive Recurrent Serous Ovarian Cancer

France, Italy, Korea, Republic of, Spain, United Kingdom, Germany, Belgium, Israel, Portugal, Netherlands, Switzerland, Canada, Australia
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

High-dose ICE With Amifostine

Sarcoma | Kidney Cancer | Testicular Germ Cell Tumor | Head and Neck Cancer | Ovarian Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Bladder Cancer | Extragonadal Germ Cell Tumor | Carcinoma of Unknown Primary

United States
EMD Serono

Completed

A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer

Ovarian Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Massachusetts General Hospital

Terminated

Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment

Recurrent Ovarian Cancer | Platinum Sensitive Ovarian Cancer

United States
Vejle Hospital
Abbott

Completed

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation (Veli-BRCA)

Recurrent, Epithelial Ovarian Cancer

Denmark
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

Melanoma | Malignant Mesothelioma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Gestational Trophoblastic Tumor | Cervical Adenocarcinoma and other conditions

United States
JSehouli
GlaxoSmithKline

Unknown

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Ovarian Cancer

Germany
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Sarcoma | Glioblastoma | Recurrent Ovarian Carcinoma | Recurrent Uterine Corpus Carcinoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Metastatic Renal Cell Cancer | Recurrent Lung Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage... and other conditions

United States
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Ovarian Epithelial Cancer Recurrent

India
Chong Kun Dang Pharmaceutical

Completed

Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

Epithelial Ovarian Cancer

Korea, Republic of
NHS Greater Glasgow and Clyde
Boehringer Ingelheim; Cancer Research UK; European Organisation for Research... and other collaborators

Unknown

Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium (NiCCC)

Ovarian Clear Cell Carcinoma | Endometrial Clear Cell Carcinoma

United Kingdom
University of Miami

Withdrawn

LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma

Ovarian Cancer | Recurrent Ovarian Carcinoma | Ovarian Carcinoma | Recurrent Ovarian Cancer
National Cancer Institute (NCI)

Completed

Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Withdrawn

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal... and other conditions
MEI Pharma, Inc.

Completed

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer (OVATURE)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Spain, Belgium, United Kingdom, Australia, Italy, Poland
MEI Pharma, Inc.

Completed

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Australia
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

Cancer

United States, Canada
National Cancer Institute (NCI)

Completed

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Sarcoma

United States
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Canada
Radboud University Medical Center
PharmaMar

Unknown

Improving Quality of Care for Patients With Recurrent Ovarian Cancer

Quality of Life | Ovarian Neoplasms
University of Southern California
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Recurrent Prostate Cancer | Stage III Renal Cell Cancer | Recurrent Endometrial Carcinoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IIIA Breast... and other conditions

United States
Regeneron Pharmaceuticals
National Cancer Institute (NCI)

Completed

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Cancer

United States
Regeneron Pharmaceuticals
National Cancer Institute (NCI)

Completed

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Cancer

United States
Cancer Research UK

Completed

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Breast Cancer | Ovarian Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United Kingdom
Merrimack Pharmaceuticals
Sanofi

Completed

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous...

United States
ARCAGY/ GINECO GROUP

Completed

A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse (REV)

Ovarian Cancer Recurrent

France
Sanofi

Completed

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Ovarian Cancer

United States
Sanofi

Completed

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Ovarian Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms | Nausea and Vomiting

United States
National Cancer Institute (NCI)

Completed

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

Fallopian Tube Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Female Reproductive Cancer

United States
Daniela Matei, MD
Bayer; Hoosier Cancer Research Network

Terminated

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Bayer

Terminated

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Malignant Ovarian Clear Cell Tumor | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian... and other conditions

Search clinical trials for: recurrent ovarian epithelial cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations